title: Successful treatment of SAPHO syndrome with adalimumab: a case report.
abstract: SAPHO syndrome is a disorder involving the skin, bone and joints. The underlying causes of SAPHO are poorly understood, and treatment is, therefore, directed towards the individual symptoms. However, many patients are refractory to treatment, and new treatment options are needed. Herein, we describe a 28-year-old patient with SAPHO syndrome and palmoplantar pustulosis seen at our hospital. Treatment was initiated with non-steroidal anti-inflammatory drugs, but clinical improvement was poor. The addition of sulfasalazine and oral alendronate also failed to alleviate symptoms. We subsequently commenced treatment with adalimumab 40 mg every 15 days and suspended bisphosphonates. Following 4 weeks' treatment with adalimumab, there was clear articular improvement and disappearance of palmoplantar pustulous lesions. Nocturnal inflammatory lumbar pain and global disease assessment were also improved. To our knowledge, this is the first report on the use of adalimumab for SAPHO. More studies are required to confirm our findings.
authors.affiliation: Unit of Rheumatology, Department of Internal Medicine, Hospital Comarcal de l'Alt Penedès, Vilafranca del Penedès, Spain. ivancastellvi@hotmail.com
authors.forename: Ivan
authors.initials: I
authors.lastname: Castellví
authors.forename: Maria
authors.initials: M
authors.lastname: Bonet
authors.forename: Jose A
authors.initials: JA
authors.lastname: Narváez
authors.forename: Jose C
authors.initials: JC
authors.lastname: Molina-Hinojosa
mesh_terms: D020083:Acquired Hyperostosis Syndrome / Q000628:therapy*; D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab
references.citation: J Am Acad Dermatol. 2005 May;52(5 Suppl 1):S118-20
references.pmid: 15858507
references.citation: Baillieres Clin Rheumatol. 1994 May;8(2):333-62
references.pmid: 8076391
references.citation: Ann Rheum Dis. 2002 Apr;61(4):375-6
references.pmid: 11874849
references.citation: Semin Arthritis Rheum. 1999 Dec;29(3):159-71
references.pmid: 10622680
references.citation: Expert Opin Investig Drugs. 2006 Oct;15(10):1229-33
references.pmid: 16989598
references.citation: Arthritis Rheum. 2002 Jul;46(7):1965-8
references.pmid: 12124882
references.citation: Rheumatol Int. 2009 Apr;29(6):713-5
references.pmid: 18998139
references.citation: Semin Arthritis Rheum. 2008 Apr;37(5):299-306
references.pmid: 17976692
references.citation: Rheumatology (Oxford). 2004 May;43(5):658-61
references.pmid: 14983108
references.citation: Ann Rheum Dis. 1988 Oct;47(10):809-15
references.pmid: 3058054
references.citation: Clin Exp Rheumatol. 1988 Apr-Jun;6(2):109-12
references.pmid: 2972430